Cytori Reports First Quarter 2015 Business and Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/5/2026
- Nasdaq hits record high as investors focus on earnings
- Oil slips on rising Mideast crude exports, G7 stocks release
- Intel stock slides as TSMC explores Terafab tie-up, analyst flags share losses
- Schneider Electric to acquire PTC for $22.6 billion in all-cash deal
- Five things to watch in markets in the week ahead
- Alaska LNG shipping savings justifies billions in investment, developer says
- Citi cuts investment banking analyst program to two years - Bloomberg
- Nasdaq hits record high as investors focus on earnings
- Paramount Skydance to close WBD deal, change ticker to SKYD
- This multi-trillion stock is "cheap and getting cheaper": Morgan Stanley
Ascendiant Capital Starts Cytori Therapeutics, Inc. (CYTX) at Buy
May 12, 2015 6:55 AM EDTAscendiant Capital initiated coverage on Cytori Therapeutics, Inc. (NASDAQ: CYTX) with a Buy rating and a price target of $1.25.
For an analyst ratings summary and ratings history on Cytori Therapeutics, Inc. click... More
Cytori Therapeutics (CYTX) Reports In-Line Q1 Loss of 7c/Share
May 11, 2015 4:23 PM EDTCytori Therapeutics (NASDAQ: CYTX) reported Q1 EPS of ($0.07), in-line with the analyst estimate of ($0.07). Revenue for the quarter came in at $900 thousand versus the consensus estimate of $2.44 million.
For earnings history and earnings-related data on Cytori Therapeutics (CYTX) click here.
... More


